Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 4.5    
    

 
 

License Agreement    
    

        Effective August 20, 2002 ("EFFECTIVE DATE"), GeneType AG, a wholly owned subsidiary of Genetic Technologies Limited, having an office at 60-66
Hanover Street, Fitzroy, Victoria 3065, Australia ("LICENSOR") and Perlegen Sciences, Inc., having an office at 2021 Stierlin Court, Mountain View, California, 94043 ("LICENSEE"), agree as
follows: 

ARTICLE I
 BACKGROUND  

	1.1
	LICENSOR
represents that it has certain intellectual property rights pertaining to genetic analysis technologies in respect to which it is prepared to grant a license to LICENSEE.

	1.2
	LICENSEE
wishes to acquire a license under and to obtain access to LICENSOR's intellectual property rights. 

ARTICLE II
 GENERAL DEFINITIONS AND RELATIONSHIPS AMONG DEFINITIONS  

	2.1
	"AFFILIATE"
means any corporation or business entity which is controlled by LICENSEE. For the purpose of this Section 2.1, the word "control" means the ownership and control,
directly or indirectly, of at least 80% of the voting shares entitled to vote in the election of directors of the corporation or entity, and in the context of a partnership, joint venture or other
form of business enterprise the right to receive at least 80% of the net proceeds of such enterprise.

	2.2
	"AGREEMENT"
means this document, its attachments, all addenda, schedules, exhibits, appendices, and any amendments to the foregoing.

	2.3
	"HIGH
RESOLUTION, WHOLE GENOME ANALYSIS" means genetic analysis using or based upon, in whole or in part, the genotyping of more than One Hundred Thousand (100,000) putative single
nucleotide polymorphisms, such polymorphisms found in Three (3) or more chromosomes of the relevant organism.

	2.4
	"EXCLUSIVITY
PERIOD" means the period extending from the EFFECTIVE DATE until the earlier of (a) one year from the date the claims provided by LICENSEE pursuant to
Section 4.1.1(c) herein issue and (b) August 31, 2006.

	2.5
	"FIELD
OF USE" means genetic analysis of mammal species using or based upon HIGH RESOLUTION, WHOLE GENOME ANALYSIS.

	2.6
	"LICENSED
PATENT(S)" means the patents and applications listed in Appendix "A" attached to this AGREEMENT and all reissues, reexaminations, divisionals, continuations,
continuations-in-part, substitutions, and extensions of the foregoing, applications therefore, any patents or applications claiming priority to any of the patents or
applications listed in Appendix A, and patents which may issue upon such applications, and foreign counterparts of the foregoing.

	2.7
	"TERM"
means the term of the last to expire LICENSED PATENT, except as otherwise provided in Article 7.

	2.8
	"LICENSED
PRODUCT(S)" means LICENSEE's products and/or services of their own design that but for the license granted herein would infringe or contribute to the infringement of one or
more claims of a LICENSED PATENT. 

1

 
	2.9
	LICENSOR
and LICENSEE are hereunder commonly referred to as "parties" (in singular and plural usage, as required by the context).

	2.10
	"TERRITORY"
means worldwide.

	2.11
	"PERLEGEN
ENTITIES" means any corporation or business entity which (i) is incorporated or organized by LICENSEE and not any third party and (ii) is controlled by,
controls, or is under common control with LICENSEE. For the purposes of this Section 2.11, the word "control" means the ownership and control, directly or indirectly, of at least 80% of the
voting shares entitled to vote in the election of directors of the corporation or entity, and in the context of a partnership, joint venture or other form of business enterprise the right to receive
at least 80% of the net proceeds of such enterprise. For purposes of clarity "PERLEGEN ENTITIES" do not and shall not include Affymetrix, Inc. 

ARTICLE III
 RELEASE  

	3.1
	LICENSOR
agrees that, provided that LICENSEE fully and faithfully discharges all obligations undertaken by it in this AGREEMENT, including, but not limited to, the confidentiality
obligations and the obligation to pay fees, LICENSOR shall release, acquit and forever discharge LICENSEE and all purchasers and users of LICENSED PRODUCTS acquired from LICENSEE from all claims,
demands, and rights of action which LICENSOR may now have on account of any infringement of any LICENSED PATENT, by performance, prior to the EFFECTIVE DATE, of acts licensed hereunder. Failure of
LICENSEE at any time to so discharge its obligations pursuant to the terms of this AGREEMENT shall constitute a waiver of the benefits of this Section 3.1 and shall forthwith restore to
LICENSOR its full rights as they existed on the EFFECTIVE DATE; provided, however, that any termination by LICENSEE of this AGREEMENT pursuant to Sections 7.2 or 7.3 shall not constitute such a waiver
and this Section 3.1 shall remain in full force and effect notwithstanding such termination if LICENSEE is not in breach of this AGREEMENT on the date of such termination. LICENSOR further
agrees not to exercise any such rights against LICENSEE, its AFFILIATES, any PERLEGEN ENTITY, and/or any purchaser and/or user of any LICENSED PRODUCTS acquired from LICENSEE prior to the EFFECTIVE
DATE during the TERM; provided, that, LICENSEE is in compliance with this AGREEMENT. 

ARTICLE IV
 GRANT TO LICENSEE  

	4.1
	Subject
to the remaining terms of this AGREEMENT, LICENSOR hereby grants and agrees to grant to LICENSEE, during the EXCLUSIVITY PERIOD of this AGREEMENT, an exclusive (but for
licenses granted prior to the EFFECTIVE DATE and disclosed in Appendix "C" attached to this AGREEMENT), nonassignable (except as otherwise provided for herein), royalty-free license under
the LICENSED PATENTS to make, have made, use, sell, offer for sale, distribute, and import LICENSED PRODUCTS in the FIELD OF USE throughout the TERRITORY.

	4.1.1
	LICENSOR
agrees to a) provide LICENSEE reasonable access to and allow LICENSEE to comment upon the prosecution of at least one patent application entitled to the benefit of
priority to U.S. Patent No. 5,612,179, U.S. Patent No. 5,851,762, or a patent application to which U.S. Patent No. 5,612,179 or U.S. Patent No. 5,851,762 claims priority,
and b) reasonably respond to such comments, and c) allow LICENSEE to provide reasonable claims for presentation in such at least one such patent application, and d) use reasonable
efforts in the prosecution of such claims. All costs of patent prosecution will be borne by LICENSOR.

	4.1.2
	In
the event that LICENSEE becomes aware of infringement of the LICENSED PATENTS in the FIELD OF USE during the EXCLUSIVITY PERIOD by an entity that did not have operations, 

2

 

products,
or services in the field of HIGH RESOLUTION, WHOLE GENOME ANALYSIS prior to the EFFECTIVE DATE, LICENSEE may provide written notice to LICENSOR, along with reasonable evidence of such
infringement. LICENSOR may, at its option, within ninety (90) days of such notice elect to bring action in the appropriate court to halt such infringement in at least the FIELD OF USE. In the
event that LICENSOR does not elect to bring an action to halt such infringement, LICENSEE and/or any PERLEGEN ENTITY shall be permitted, but not required, to bring such action in its own name, at its
own expense, and on its own behalf; provided however, that LICENSEE's and/or any PERLEGEN ENTITY's choice of counsel in pursuing such action must first meet with the reasonable approval of LICENSOR,
and LICENSOR shall have reasonable access to all papers, including, but not limited to claims, pleadings, briefs, motions, declarations, and affidavits, prior to filing with the court as well as an
opportunity to comment on such papers prior to their filing. In either event, the other party shall provide reasonable cooperation in such action, including, if required by the relevant court, to
allow its name to be added to any pleadings or complaint. 

	4.1.3
	In
the event that an action is brought pursuant to Section 4.1.2, the party bringing such action shall be entitled to, in any settlement of such action, recovery of all of
its costs of enforcement first from any monies obtained in such settlement. Thereafter, the other party shall be allowed to recover 1/2 of all such monies directly attributable to the
LICENSED PATENTS in the FIELD OF USE.

	4.1.4
	In
connection with a settlement of an action brought pursuant to Section 4.1.2, LICENSEE shall be entitled to sublicense its rights in the LICENSED PATENTS in the FIELD OF
USE during the EXCLUSIVITY PERIOD. LICENSOR shall reasonably cooperate in such licensing activities to provide such licensees with at least non exclusive rights in the FIELD OF USE during the period
after the EXCLUSIVITY PERIOD, under reasonable terms and conditions based upon LICENSOR's then going licensing terms to a similarly situated (in terms of territory, field of use, licensed patents,
product/service market, anticipated profits, and rights granted) licensee.

	4.1.5
	LICENSOR
will use reasonable efforts to maintain the LICENSED PATENTS including, but not limited to paying all relevant maintenance fees, and responding to actions from the relevant
patent offices and/or third parties.

	4.2
	Subject
to the remaining terms of this AGREEMENT, LICENSOR hereby grants and agrees to grant to LICENSEE, after the EXCLUSIVITY PERIOD, but during the TERM of this AGREEMENT, a
non-exclusive, nonassignable (except as otherwise provided for herein), royalty-free, license under the LICENSED PATENTS (without the right to sublicense) to make, have made,
use, sell, offer for sale, distribute, and import LICENSED PRODUCTS in the FIELD OF USE throughout the TERRITORY.

	4.3
	LICENSEE
may extend this AGREEMENT to its AFFILIATES and/or to the PERLEGEN ENTITIES provided that such AFFILIATES and/or PERLEGEN ENTITIES, as the case may be, are bound by the terms
of this AGREEMENT. Upon receiving written notice from LICENSEE regarding it interest in extending this AGREEMENT to cover additional species, LICENSOR agrees to enter into good faith negotiations with
LICENSEE for a license, on reasonable terms and conditions, for such additional species based upon LICENSOR's then going licensing terms to a similarly situated (in terms of territory, field of use,
licensed patents, product/service market, anticipated profits, and rights granted) licensee.

	4.4
	The
rights and licenses granted by LICENSOR in this AGREEMENT are personal to LICENSEE. LICENSEE shall not assign or otherwise transfer any license or right granted hereunder or any
interest therein except as specifically provided in this Agreement, without the written consent of LICENSOR (which may be withheld in LICENSOR's sole and absolute discretion). Any attempted 

3

 

assignment
or transfer in violation hereof shall be void and shall automatically terminate all rights of LICENSEE under this AGREEMENT. 

ARTICLE V
 PAYMENTS  

	5.1
	Subject
to the terms and conditions specified below, as consideration for the rights and licenses granted by this AGREEMENT, LICENSEE will pay to LICENSOR a) within five
(5) days of the last execution of this AGREEMENT the sum of Two Hundred Fifty Thousand United States Dollars ($250,000.00), and b) within six (6) months of the last execution of
this AGREEMENT the sum of One Hundred Fifty Thousand United States Dollars ($150,000.00), such sums collectively representing a one-time, nonrefundable license issue fee.

	5.2
	As
additional consideration for the rights and licenses granted by this AGREEMENT, LICENSEE agrees to enter into the subscription agreement in Appendix "B", issuing 127,000 shares of
LICENSEE's Series B Preferred Stock to LICENSOR. 

ARTICLE VI
 WAIVER  

	6.1
	No
waiver by either party, express or implied, of any breach of any term, condition, or obligation of this AGREEMENT by the other party shall be construed as a waiver of any
subsequent breach of that term, condition, or obligation, or of any other term, condition, or obligation of this AGREEMENT of the same or different nature. 

ARTICLE VII
 TERM AND TERMINATION OF AGREEMENT  

	7.1
	This
AGREEMENT shall extend from the EFFECTIVE DATE hereof for the TERM, unless terminated earlier as provided below.

	7.2
	Either
party shall have the right to terminate this AGREEMENT upon any material breach of any term or condition of this AGREEMENT by the other party, which has not been corrected
within thirty (30) days after receipt of a notice in writing with reference to this Section 7.2. LICENSOR shall have the right to terminate this AGREEMENT in the event that LICENSEE
shall become involved in insolvency, dissolution, bankruptcy, or receivership proceedings affecting the operation of its business, or in the event that LICENSEE discontinues business for any reason.
In the event of termination of this AGREEMENT all rights granted to LICENSEE hereunder shall revert to LICENSOR.

	7.3
	LICENSEE
shall have the right to terminate this AGREEMENT after June 1, 2003 upon thirty (30) days written notice to LICENSOR.

	7.4
	Expiration
or termination of this AGREEMENT pursuant to this Article VII shall not (i) relieve a party hereto of any obligation accruing to such party prior to such
expiration or termination or (ii) result in the waiver of any right or remedy by a party hereto accruing to such party prior to such expiration or termination.

	7.5
	SURVIVAL:
Section 7.4, Article III, Article VI, Article VIII, Article IX, Article X, and all payment obligations incurred prior to
termination shall survive the termination of this AGREEMENT. 

4

 
ARTICLE VIII
 CONFIDENTIALITY, PUBLICITY AND PRESS RELEASES  

	8.1
	DISCLOSURE
AND USE: The Parties agree that the terms and conditions set forth in this AGREEMENT shall be deemed confidential information ("CONFIDENTIAL INFORMATION") hereunder. Both
parties agree to treat all CONFIDENTIAL INFORMATION in the same manner as it treats its own similar proprietary information, but in no case will the degree of care be less than reasonable care. The
parties shall use the CONFIDENTIAL INFORMATION only in performing under this AGREEMENT and shall retain the CONFIDENTIAL INFORMATION in confidence and not disclose to any third party (except as
authorized under this AGREEMENT) without the other party's express written consent. The parties shall disclose the CONFIDENTIAL INFORMATION only to those employees and contractors who have a need to
know such information for the purposes of this AGREEMENT, and such employees and contractors must have entered into agreements containing confidentiality provisions covering the CONFIDENTIAL
INFORMATION, or similar confidential information, with terms and conditions at least as restrictive as those set forth herein.

	8.2
	PERMITTED
USE AND DISCLOSURES: Each party hereto may use or disclose CONFIDENTIAL INFORMATION to the extent such use or disclosure is reasonably necessary in prosecuting or defending
litigation, complying with applicable law, stock exchange rules, governmental regulation or court order, submitting information to tax or other governmental authorities, or otherwise exercising its
rights hereunder.

	8.3
	PUBLICITY
AND PRESS RELEASES: LICENSOR or LICENSEE may issue appropriate notifications to relevant stock exchanges and issue one or more appropriate media/press releases with regard
to the existence of this AGREEMENT within seven (7) days of the EFFECTIVE DATE or as soon as reasonably practical thereafter, provided that the other party is allowed to reasonably comment on
such media/press release. Neither party shall publish any other press releases relating to this AGREEMENT without prior written approval of the other party; provided however, that LICENSOR shall be
able to disclose to other licensees and/or prospective licensees the identity of LICENSEE and the existence of this AGREEMENT, but not its terms; and LICENSEE shall be able to disclose to customers
and prospective customers the identity of LICENSOR and the existence of this AGREEMENT, but not its terms. 

ARTICLE IX
 NOTICE  

	9.1
	Any
notice, request or statement hereunder shall be deemed to be sufficiently given or rendered when personally delivered, delivered by a major commercial rapid delivery courier
service or mailed by certified or registered mail, return receipt requested, and if given or rendered to LICENSEE, addressed to: 

Perlegen
Sciences, Inc.

2021 Stierlin Court

Mountain View, California 94043

Attn: General Counsel 

or,
if given or rendered to LICENSOR, addressed to: 

Dr. Mervyn
Jacobson

Executive Chairman

Genetic Technologies Limited

60-66 Hanover Street

Fitzroy, Victoria 3065

Australia 

5

 

with
a copy to: 

Michael
A. DeSanctis, Esq.

Faegre & Benson LLP

Seventeenth Street, Suite 2500

Denver, CO 80202

USA 

or,
in any case, to such changed address or person as LICENSOR or LICENSEE shall have specified to the other by written notice pursuant to the terms of this Section 9.1. 

ARTICLE X
 MISCELLANEOUS  

	10.1
	LICENSOR
warrants that it is the sole and exclusive owner of the entire right, title, and interest in and to the LICENSED PATENTS and the inventions disclosed and claimed therein,
and it has the power to grant the licenses granted herein. LICENSOR further warrants that there are no pending, or to LICENSOR's knowledge, threatened actions, suits, proceedings or claims by others
against the LICENSED PATENTS that the LICENSED PATENTS infringe or otherwise violate any third party intellectual property right, and LICENSOR has no knowledge of any reasonable basis for any of the
foregoing or that the LICENSED PATENTS are not enforceable.

	10.2
	LICENSEE
warrants and represents that (i) it is knowledgeable about the field of genome analysis; and (ii) is not reasonably aware of an entity having operations,
products, or services in the field of HIGH RESOLUTION, WHOLE GENOME ANALYIS.

	10.3
	Nothing
contained in this AGREEMENT shall be construed as:

	(a)
	a
warranty or representation by LICENSOR as to the validity or scope of any LICENSED PATENT; or

	(b)
	a
warranty or representation that any manufacture, sale, lease, use or other disposition hereunder will be free from infringement of patents other than those under which and to the
extent to which licenses are in force hereunder; or

	(c)
	except
as set forth in Section 4.1.2 herein, an agreement to bring or prosecute actions or suits against third parties for infringement or conferring any right to bring or
prosecute actions or suits against third parties for infringement; or

	(d)
	except
as set forth in Section 8.3 herein, conferring any right to use by either party, in advertising, publicity, or otherwise, any trademark, trade name or name, or any
contraction, abbreviation or simulation thereof, of the other party; or

	(e)
	conferring
by implication, estoppel or otherwise, upon LICENSEE, any license or other right under any intellectual property or patent, except that expressly granted hereunder.

	10.4
	INDEMNIFICATION:

	(a)
	LICENSEE
agrees to hold LICENSOR harmless from any claims by third parties arising from the manufacture, use, sale, importation, or other disposition of LICENSED PRODUCTS by LICENSEE.
LICENSEE shall be fully responsible for all aspects of developing expertise and proficiency with regard to manufacturing, use, and sale, of LICENSED PRODUCTS and in this respect it shall indemnify,
hold harmless, and defend LICENSOR, and LICENSOR's subsidiaries, affiliates, officers, directors, representatives, employees, or agents against any and all claims, causes of action, demands,
judgments, settlements, expenses, or losses (collectively, "CLAIMS"), including, but not limited to, reasonable attorneys' fees and or agents against any and all claims, causes of action, demands,
judgments, settlements, expenses, or losses 

6

 

(collectively,
"CLAIMS"), including, but not limited to, reasonable attorneys' fees and court costs, arising out of or in connection with: a) the design, development, manufacture, use,
packaging, distribution, or shipment of LICENSED PRODUCTS; b) any breach of any representation, warranty, or covenant of LICENSEE hereunder; or c) the failure of LICENSEE to perform any
covenants or obligations contained in this AGREEMENT. LICENSEE shall have the exclusive right to control the defense of any such CLAIM, including the right to select counsel and to settle any claim,
provided that LICENSEE shall consult with LICENSOR, and obtain LICENSOR's consent, which shall not be unreasonably withheld or delayed, before settling any claim that affects the LICENSED PATENTS. The
obligations of LICENSEE set forth in this Section 10.4(a) shall apply only if LICENSOR notifies LICENSEE in writing within 15 days following receipt of written notice of any CLAIM
brought against LICENSOR in respect of which LICENSOR intends to invoke the provisions of this Section 10.4(a). LICENSEE shall keep LICENSOR informed on a current basis of its defense of any
claims pursuant to this Section 10.4(a). 

	(b)
	LICENSOR
shall indemnify, hold harmless, and defend LICENSEE, its AFFILIATES, the PERLEGEN ENTITIES, and their respective subsidiaries, officers, directors, representatives,
employees, and/or agents against any and all CLAIMS, including, but not limited to, reasonable attorneys' fees and court costs, arising out of or in connection with: a) any breach of any
representation, warranty, or covenant of LICENSOR hereunder or b) the failure of LICENSOR to perform any covenants or obligations contained in this AGREEMENT. LICENSOR shall have the exclusive
right to control the defense of any such CLAIM, including the right to select counsel and to settle any claim, provided that LICENSOR shall consult with LICENSEE, and obtain LICENSEE's consent, which
shall not be unreasonably withheld or delayed, before settling any claim. The obligations of LICENSOR set forth in this Section 10.4(b) shall apply only if LICENSEE notifies LICENSOR in writing
within 15 days following receipt of written notice of any CLAIM brought against LICENSEE in respect of which LICENSEE intends to invoke the provisions of this Section 10.4(b). LICENSOR
shall keep LICENSEE informed on a current basis of its defense of any claims pursuant to this Section 10.4(b). 

	10.5
	CONSTRUCTION:
This AGREEMENT has been negotiated by the parties and their respective counsel. This AGREEMENT shall be interpreted fairly in accordance with its terms and without any
strict construction in favor of or against either party. This AGREEMENT shall not be construed in favor or against either party by reason of the authorship of any provisions hereof. The existence or
absence of any term or condition of this AGREEMENT shall not be used in the construction or interpretation of any other agreement between the parties. The existence or absence of any term or condition
of any other agreement between the parties shall not be used in the construction or interpretation of this AGREEMENT.

	10.6
	DUE
DILIGENCE: LICENSEE understands that market presence is an important factor in LICENSOR's decision to enter into this AGREEMENT. Accordingly, LICENSEE agrees to use its
commercially reasonable efforts to develop expertise and proficiency in the manufacture, use, and /or sale of LICENSED PRODUCTS in the FIELD OF USE.

	10.7
	MARKINGS:
LICENSEE shall use markings as LICENSOR may reasonably request from time to time, including, but not limited to, marking the LICENSED PRODUCTS and/or documentation related
thereto with patent number(s).

	10.8
	MODIFICATION:
This AGREEMENT sets forth the entire agreement and understanding between the parties as to the subject matter of this AGREEMENT and merges all prior discussions between
the parties, and no one of the parties shall be bound by any modification of this AGREEMENT, or by any conditions, definitions, warranties, or representations with respect to the subject matter of
this AGREEMENT, other than as expressly provided for herein, or as duly 

7

 

set
forth on or subsequent to the EFFECTIVE DATE in writing and signed by duly authorized representatives of the party to be bound thereby. 

	10.9
	CHOICE
OF LAW: This AGREEMENT and matters connected with the performance thereof shall be construed, interpreted, applied and governed in all respects in accordance with the laws of
New York, and the parties hereto submit and consent to jurisdiction and venue in New York, New York, except to the extent preempted by federal jurisdiction in which case such jurisdiction shall be in
the Federal courts of New York.

	10.10
	ARBITRATION:
Notwithstanding Section 10.9 above, other than injunctive relief or pre-award attachment of assets which may, but need not be, pursued in a court of
law, the parties agree that any controversy or claim arising under this AGREEMENT shall be submitted to binding arbitration in New York, New York pursuant to the Rules of Arbitration of the American
Arbitration Association (AAA) by an arbitral tribunal comprised of three arbiters. Each party shall nominate one arbiter appointed in accordance with the Rules. If a party fails to nominate an arbiter
within thirty (30) days from the date on which the claimant's demand for arbitration has been communicated to the other party, the AAA shall make such appointment. The two arbiters so appointed
shall agree upon a third arbiter who shall act as chair of the arbitral tribunal. If the two arbiters fail to nominate a chair within forty-five (45) days from the second of the two
appointments, the AAA shall select the chair. The language of the arbitration shall be in English. The parties agree to exclude any right to appeal to any court of law on the merits of the dispute,
and judgment on the award rendered by the arbitrators may be entered in any court having jurisdiction over the award, either of the parties, or their assets.

	10.11
	GOVERNING
DOCUMENT: This AGREEMENT may be translated into languages other than English for the convenience of the parties hereto provided, however, the English language version of
this AGREEMENT shall be the governing version and shall not be affected by the interpretation of any other language versions.

	10.12
	ATTORNEYS'
FEES: Upon resolution of any claim or controversy arising under this AGREEMENT, the prevailing party shall be awarded its reasonable attorneys' fees and costs in addition
to any other amount awarded.

	10.13
	DISCLAIMER
OF WARRANTIES: Except as expressly set forth herein, EACH PARTY EXPRESSLY DISCLAIMS, TO THE EXTENT ALLOWED BY APPLICABLE LAW, ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS
OR IMPLIED, INCLUDING WITHOUT LIMITATION THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE (EVEN IF INFORMED OF SUCH PURPOSE), NONINFRINGEMENT OF THE INTELLECTUAL PROPERTY
RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO.

	10.14
	LIMITATION
OF LIABILITY: EXCEPT FOR BREACH OF PAYMENT TERMS UNDER ARTICLE 5 OR FOR LIABILITY FOR BREACH OF ARTICLE 8, NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY
ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT OR ANY LICENSE GRANTED HEREUNDER.

	10.15
	INDEPENDENT
BUSINESS: LICENSEE acknowledges that its business operation is completely independent of LICENSOR and LICENSEE shall at no time hold itself out as an agent or
representative of LICENSOR. No partnership, joint venture, or other relationship shall be deemed to exist by virtue of this AGREEMENT. 

8

 
	10.16
	INDEPENDENT
TERMS: All the terms of this AGREEMENT shall be independent and unconditional so that the performance of any one term shall not be subject to any set off or
counterclaim.

	10.17
	SEVERABILITY:
In the event any clause or term of this AGREEMENT is determined to be void, invalid, or unenforceable, the clause shall be stricken to the extent necessary in order to
overcome the limitation and as revised this AGREEMENT shall remain in full force and effect.

	10.18
	ASSIGNMENT:
This AGREEMENT may not be assigned by LICENSEE except to (i) any PERLEGEN ENTITY or (ii) any business acquiring substantially all of the relevant business
assets of LICENSEE; provided however, that the products and/or services of such acquiring company's pre-existing business shall not be considered "LICENSED PRODUCT(S)" as a result of such
acquisition or as a result of such assignment. Any other attempt to extend the rights and licenses granted herein to such business shall be void and shall automatically terminate this AGREEMENT.

	10.19
	HEADINGS:
The headings contained within this AGREEMENT are for convenience and reference purposes only. They do not form a part hereof and shall not affect the meaning or
interpretation of this AGREEMENT.

	10.20
	FURTHER
ASSURANCES: The parties hereto shall execute such further documents and perform such further acts as may be necessary to comply with the terms of this AGREEMENT and
consummate the transactions herein provided.

	10.21
	FORCE
MAJEURE: Neither party shall be held responsible if the fulfillment of any terms or provisions of this AGREEMENT are delayed or prevented by wars, revolutions, fires, floods,
acts of God or other cause not within the control of the party whose performance is interfered with, and which by the exercise of reasonable diligence, the party is unable to prevent.

	10.22
	COUNTERPARTS:
This AGREEMENT may be executed in counterparts (including facsimile signatures), each of which will be deemed an original and all of which together constitute one
instrument. 

        IN
WITNESS WHEREOF, the parties hereto have caused their authorized representatives to execute this AGREEMENT. 

	LICENSOR:	 	LICENSEE:
	

GeneType AG	
 	

Perlegen Sciences, Inc.
	

By	

    
	
 	

By	

    

	

    
 Printed Name/Date	
 	

    
 Printed Name/Date
	

    
 Title	
 	

    
 Title

9

 
 
 

APPENDIX "A"
  Licensed Patents    
    

United
States Patent Nos. 5,612,179; 5,851,762; 5,192,659; 5,789,568; and 5,096,557 

United
States Patent Application Nos. 551,239, 465,863, 405,499, 398,217, 949,652, 971,856, 550,939, 550,940 

10

 
 
 

APPENDIX "B"
  Subscription Agreement    
    

PERLEGEN SCIENCES, INC.  

 SUBSCRIPTION AGREEMENT  

        This Subscription Agreement (this "Agreement") is made by and among PERLEGEN SCIENCES,
INC., a Delaware corporation (the "Company"), and GENETYPE AG, a wholly owned
subsidiary of Genetic Technologies Limited, having an office at 60-66 Hanover Street, Fitzroy, Victoria 3065, Australia ("Purchaser"). 

        1.    Purchase.    Subject to the terms and conditions of this Agreement, the Company agrees to sell to Purchaser, and
Purchaser agrees to purchase from the Company, One Hundred Twenty-Seven Thousand (127,000) shares of Series B Preferred Stock), at a price of $3.60 per share (the
"Shares"). The consideration for the Shares shall be in the form of a license of the Licensed Patents (as listed on Appendix A of the License
Agreement) from the Purchaser to the Company pursuant to that certain Licensing Agreement, by and between the Purchaser and the Company, of even date herewith (the "License
Agreement"). 

        2.    Delivery and Payment.    The Company will deliver to Purchaser a certificate or certificates, registered in
Purchaser's name, representing the Shares against receipt of the executed License Agreement from the Purchasers. 

        3.    Rights of Refusal.    

        (a)    Transfer Notice.    If at any time, or from time to time, the Purchaser proposes to transfer any or all of the
Shares, or the Common Stock of the Company into which the Shares are convertible (the "Conversion Shares"), to one or more third parties (a
"Transfer"), then the Purchaser shall give the Company written notice of the Purchaser's intention to make the Transfer (the
"Transfer Notice"), which Transfer Notice shall include (i) a description of the securities to be transferred ("Offered
Shares"), (ii) the identity of the prospective transferee(s) and (iii) the consideration and the material terms and conditions upon which the proposed Transfer is
to be made. 

        (b)    Company's Option.    The Company shall have an option for a period of ten (10) business days from the
Company's receipt of the Transfer Notice to elect to purchase all or any portion of the Offered Shares at the same price and subject to the same material terms and conditions as described in the
Transfer Notice. The Company may exercise such purchase option and, thereby, purchase all or any portion of the Offered Shares by notifying the Purchaser in writing before expiration of such ten
(10) business day period as to the number of such shares which it wishes to purchase. If the Company gives the Purchaser notice that it desires to purchase such shares, then such notice shall
constitute an irrevocable commitment to purchase such shares and payment for the Offered Shares shall be by check or wire transfer, against delivery of the Offered Shares to be purchased at a place
agreed upon between the parties and at the time of the scheduled closing therefor, which shall be no later than thirty (30) business days after the Company's receipt of the Transfer Notice,
unless the Transfer Notice contemplated a later closing with the prospective third party transferee(s) or unless the value of the purchase price has not yet been established pursuant to
Section 3(c) or unless antitrust or other regulatory approvals or expirations of legally mandated waiting periods require a closing at a later date. 

        (c)    Valuation of Property.    Should the purchase price specified in the Transfer Notice be payable in property
other than cash or evidences of indebtedness, the Company shall have the 

11

 

right
to pay the purchase price in the form of cash equal in amount to the fair market value of such property, as determined in good faith by the Board of Director's of the Company. 

        (d)    Non-Exercise of Rights.    In the event that the Company has not exercised its right to purchase
the Offered Shares within the time period specified in this Section 3, the Purchaser shall have a period of sixty (60) days from the expiration of such rights (or such longer period as
is necessary to comply with any applicable regulatory waiting period or obtain any applicable regulatory approval) in which to sell the Offered Shares upon terms and conditions (including the purchase
price) no more favorable than those specified in the Transfer Notice to the third-party transferee(s) identified in the Transfer Notice. The third-party transferee(s) shall acquire the Offered Shares
free and clear of subsequent rights of first refusal under this Agreement. In the event the Purchaser does not consummate the sale or disposition of the Offered Shares within the sixty (60) day
period from the expiration of these rights (or such longer period as is necessary to comply with any applicable regulatory waiting period or obtain any applicable regulatory approval), the Company's
first refusal rights shall continue to be applicable to any subsequent disposition of the Offered Shares by the Purchaser until such right lapses in accordance with the terms of this Agreement.
Furthermore, the exercise or non-exercise of the rights of the Company under this Section 3 to purchase equity securities from the Purchaser shall not adversely affect their rights
to make subsequent purchases from the Purchaser of equity securities. 

        (e)   Notwithstanding
the foregoing, any attempt by the Purchaser to transfer equity securities in violation of Section 2 hereof shall be void and the Company will not
effect such a transfer nor will it treat any alleged transferee(s) as the holder of such shares. 

        4.    Representations of Purchaser.    Purchaser hereby represents and warrants to the Company as follows: 

        (a)    Experience.    Purchaser has experience in evaluating and investing in private placement transactions so that
Purchaser is capable of evaluating the merits and risks of Purchaser's investment in the Company. Purchaser, by reason of his, her or its business or financial experience or the business or financial
experience of his, her or its professional advisors who are unaffiliated with and who are not compensated by the Company or any affiliate or selling agent of the Company, directly or indirectly, has
the capacity to protect his, her or its own interests in connection with the purchase of the Shares hereunder. 

        (b)    Investment.    Purchaser is acquiring the Shares for investment for Purchaser's own account, not as a nominee
or agent, and not with the view to, or for resale in connection with, any distribution thereof. Purchaser understands that the Shares to be purchased and the Conversion Shares have not been, and will
not be, registered under the Securities Act of 1933, as amended (the "Securities Act"), by reason of a specific exemption from the registration
provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of Purchaser's representations as expressed herein. Purchaser
has not been formed for the specific purpose of acquiring the Shares (or the underlying Common Stock). 

        (c)    Rule 144.    Purchaser acknowledges that the Shares and the Conversion Shares must be held indefinitely
unless subsequently registered under the Securities Act or an exemption from such registration is available. Purchaser is aware of the provisions of Rule 144 promulgated under the Securities
Act which permit limited resale of shares purchased in a private placement subject to the satisfaction of certain conditions, including a requirement that the securities be held prior to resale for
the applicable holding periods specified in Rule 144, the existence of a public market for the shares, and, in some cases, the availability of certain current public information about the
Company, compliance with the manner of sale requirements of Rule 144, and the number of shares being sold during any three-month period not exceeding specified limitations. 

12

 

        (d)    No Public Market.    Purchaser understands that no public market now exists for any of the securities issued by
the Company, that the Company has made no assurances that a public market will ever exist for the Shares (or the underlying Common Stock) and that, even if such a public market exists at some future
time, the Company may not then be satisfying the current public information requirements of Rule 144. 

        (e)    Access to Data.    Purchaser and its representatives have met with representatives of the Company and thereby
have had the opportunity to ask questions of, and receive answers from, said representatives concerning the Company and the terms and conditions of this transaction as well as to obtain any
information requested by Purchaser. Any questions raised by Purchaser or his, her or its representatives concerning the transaction have been answered to the satisfaction of Purchaser and his, her or
its representatives. Purchaser's decision to purchase the Shares is based in part on the answers to such questions as Purchaser and its representatives have raised concerning the transaction and on
its own evaluation of the risks and merits of the purchase and the Company's proposed business activities. 

        (f)    Accredited Investor.    Purchaser is an "accredited investor" for purposes of Regulation D under the
Securities Act and it is able financially to bear the risks of purchasing and owning the Shares. 

        (g)    Authorization.    All corporate action on the part of Purchaser, its officers, directors and stockholders
necessary for the authorization, execution and delivery of this Agreement by Purchaser, the performance of all obligations of hereunder by Purchaser has been taken and this Agreement constitutes a
valid and legally binding obligation of Purchaser, enforceable against Purchaser in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief
of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies. 

        (h)    Tax Consequences.    Purchaser has reviewed with his, her or its own tax advisors the federal, state, local and
foreign tax consequences of this investment and the transactions contemplated by this Agreement. Purchaser is relying solely on such advisors and not on any statements or representations of the
Company or any of its agents and understands that Purchaser (and not the Company) shall be responsible for Purchaser's own tax liability that may arise as a result of this investment or the
transactions contemplated by this Agreement. 

        (i)    Foreign Purchaser.    Purchaser hereby represents that it has satisfied itself as to the full observance of the
laws of its jurisdiction in connection with any invitation to subscribe for the Shares and the Conversion Shares, its receipt of the Shares and the Conversion Shares and any use of this Agreement,
including (i) the legal requirements within its jurisdiction for the purchase or receipt of the Shares, (ii) any foreign exchange restrictions applicable to such purchase or receipt,
(iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding,
redemption, sale, or transfer of the Shares. Purchaser represents that Purchaser's subscription and payment for and continued beneficial ownership of the Shares and the Conversion Shares, will not
violate any applicable securities or other laws of the Purchaser's jurisdiction. 

        5.    Representation of Company.    The Company hereby represents and warrants to Purchaser as follows: 

        (a)    Authorization.    The Company is a corporation duly organized, validly existing and in good standing under the
laws of the State of Delaware. All corporate action on the part of the Company, its officers, directors and stockholders necessary for the authorization, execution and delivery of this Agreement, the
performance of all obligations of the Company hereunder and the authorization, issuance and delivery of the Shares and Conversion Shares has been taken and this 

13

 

Agreement
constitutes a valid and legally binding obligation of the Company, enforceable against the Company in accordance with its terms, subject to laws of general application relating to
bankruptcy, insolvency and the relief of debtors and rules of law governing specific performance, injunctive relief or other equitable remedies. 

        (b)    Valid Issuance of Securities.    The Shares being issued to Purchaser hereunder, when issued, sold and
delivered in accordance with the terms hereof for the consideration expressed herein, will be duly and validly issued, fully paid and nonassessable and free of any liens or encumbrances except as set
forth herein or in the Company Certificate of Incorporation; provided, however, that the Shares may be subject to restrictions on transfer under state and/or federal securities laws as set forth
herein. Based in part upon the representations of Purchaser in this Agreement, the Shares will be issued in compliance with all applicable federal and state securities laws. The Conversion Shares
issuable upon conversion of the Shares has been duly and validly reserved for issuance, and upon issuance in accordance with the terms of the Company's Certificate of Incorporation shall be duly and
validly issued, fully paid and non-assessable and free of any liens or encumbrances except as set forth herein or in the Company Certificate of Incorporation (provided, however, that such
Conversion Shares may be subject to restrictions on transfer under state and/or federal securities laws as set forth herein) will be issued in compliance with all applicable federal and state
securities laws. 

        6.    Qualification of Securities.    The sale of the securities that are the subject of this Agreement has not been
qualified with the Commissioner of Corporations of the State of California, and the issuance of such securities or the payment or receipt of any part of the consideration therefor prior to such
qualification is unlawful, unless the sale of securities is exempt from the qualification by Section 25100, 25102 or 25105 of the California Corporations Code. The rights of all parties to this
Agreement are expressly conditioned upon such qualification being obtained, unless the sale is so exempt. 

        7.    Legends.    Purchaser acknowledges and understands that the certificate evidencing the Shares (and the
Conversion Shares) shall bear the following legends (and any other legends required under state securities laws or otherwise in the opinion of legal counsel for the Company): 

"THE
SALE, PLEDGE, HYPOTHECATION, ASSIGNMENT OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERITIFICATE IS SUBJECT TO A RIGHT OF FIRST REFUSAL BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY.
COPIES OF SUCH RIGHT OF FIRST REFUSAL MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. ANY TRANSFER IN VIOLATION OF THE RIGHT OF FIRST REFUSAL IS VOID." 

"THE
SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE
TRANSFERRED EXCEPT (A) (1) IF REGISTERED UNDER THE SECURITIES ACT OR (2) IN A TRANSACTION EXEMPT FROM, OR NOT SUBJECT TO, SUCH REGISTRATION (IT BEING UNDERSTOOD THAT NO REPRESENTATION
CAN BE MADE AS TO THE AVAILABILITY OF AN EXEMPTION) AND (B) IN ACCORDANCE WITH ALL APPLICABLE SECURITIES LAWS OF THE STATES OF THE UNITED STATES." 

        8.    Counterparts.    This Agreement may be executed in any number of counterparts and signatures may be delivered by
facsimile, each of which may be executed by less than all parties, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall
constitute one instrument. 

14

 

        9.    Severability.    If any provision of this Agreement becomes or is declared by a court of competent jurisdiction
to be illegal, unenforceable or void, portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement and the balance of this Agreement
shall be enforceable in accordance with its terms. 

        10.    Confidentiality.    Each party hereto agrees that, except with the prior written permission of the other party,
it shall at all times keep confidential and not divulge, furnish or make accessible to anyone any confidential information, knowledge or data concerning or relating to the business or financial
affairs of the other parties to which such party has been or shall become privy by reason of this Agreement, discussions or negotiations relating to this Agreement, the performance of its obligations
hereunder or the ownership of Shares (or Common Stock receivable upon conversion of the Shares) purchased hereunder. The provisions of this Section 10 shall be in addition to, and not in
substitution for, the provisions of any separate nondisclosure agreement executed by the parties hereto with respect to the transactions contemplated hereby or contained in the License Agreement. 

        11.    General.    This Agreement shall be governed by the internal laws of the State of California, is not assignable
by any party and represents the entire agreement among the parties. This Agreement may only be modified or amended in writing with the consent of the Company and Purchaser. This Agreement and all acts
and transactions pursuant hereto shall be governed, construed and interpreted in all respects by the internal laws of the State of California, without regard to conflict of laws provisions. 

        12.    "Market Stand-off" Agreement.    Purchaser agrees not to sell or otherwise transfer or dispose of
any Common Stock (or other securities) of the Company held by it for a period not to exceed one hundred eighty (180) days following the effective date of a registration statement of the Company
filed under the Securities Act if so requested by the Company and underwriter of Common Stock (or other securities) of the Company, provided that: 

        (a)   such
agreement shall apply only to the first underwritten registered public offering of the Company; 

        (b)   such
agreement shall apply only to securities held by Purchaser prior to the effective date of such registration statement and shall not apply to the sale of any shares
to an underwriter pursuant to an underwriting agreement; and 

        (c)   all
officers and directors of the Company and all holders of 5% or more of the Company's securities enter into similar agreements. The Company may impose
stop-transfer instructions with respect to the shares (or securities) subject to the foregoing restriction until the end of such period. 

15

 

        IN
WITNESS WHEREOF, the parties have executed this Agreement on June 7, 2002. 

	"Company"	 	Perlegen Sciences, Inc.,

a Delaware corporation
	

 	
 	

By:	

    

	

 	
 	

Title:	

    

	

    	
 	

 	

 
	
"Purchaser"	
 	
GENETYPE AG, a wholly owned subsidiary of

    Genetic Technologies Limited
	

 	
 	

By:	

    

	

 	
 	

Title:	

    

16

 
 
 

APPENDIX "C"
  EXISTING LICENSES    
    

	•
	Pharmacia Corporation, having an office at 100 Route 206 North, Peapack, New Jersey, 07977 USA (limited to the internal
standards patent (the '557 patent))

	•
	Genetic Solutions Pty Ltd., having an office at 50 Meiers Road, Indooroopilly QLD 4068 Australia (limited to gene
marker tests for application in the domestic livestock and aquaculture industries)

	•
	Nanogen, Inc., having an office at 10398 Pacific Center Court, San Diego, CA 92121, USA (limited to electronic
microarray technology)

	•
	Sequenom, Inc., having an office at 3595 John Hopkins Court, San Diego, California, USA (limited to mass spectrometry
analysis) 

17

QuickLinks

Exhibit 4.5

License Agreement

APPENDIX "A" Licensed Patents

APPENDIX "B" Subscription Agreement

APPENDIX "C" EXISTING LICENSESQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 4.6    
    

 
  Myriad/Genetic Technologies Marketing and
  
    Patent License Agreement    
    

        This Myriad/Genetic Technologies Patent License Agreement ("Agreement") is entered into as of
October     , 2002 ("Effective Date") by and between the Parties, 

        Myriad
Genetics, Inc., a corporation organized under the laws of the State of Delaware, having a principal place of business at 320 Wakara Way, Salt Lake City, Utah 84108
("Myriad"), and 

        Genetic
Technologies Limited, having offices at 60-66 Hanover Street, Fitzroy, Victoria 3065, Australia ("GTG"), 

and
the Parties agree as follows. 

 
 

A R T I C L E 1
  
    BACKGROUND    
    

        1.1   Myriad
is the owner or the exclusive licensee, with the right to sublicense, of patents relating to genetic testing with respect to the BRCA1, BRCA2, MLH1, MSH2, APC,
P16 and AGT genes. 

        1.2   GTG
is interested in marketing and potentially performing current and future genetic testing services, including, but not limited to, COLARISSM, COLARIS  APSM, MELARISSM,
CardiaRisk®, and other genetic testing services provided by Myriad relating to determining a
specific DNA sequence or sequences of the MLH1, MSH2, APC, P16 and/or AGT gene(s). 

        1.3   GTG
is interested in marketing and performing certain genetic testing services and marketing genetic testing services, including, but not limited to,
BRACAnalysis®, provided by Myriad relating to determining a specific DNA sequence or sequences of the BRCA1, BRCA2 gene(s). 

        1.4   The
Parties have concluded that the needs and interests of the Parties will be served by the grant of rights and licenses from Myriad to GTG with respect to genetic
testing relating to the BRCA1, BRCA2, MLH1, MSH2, APC, P16 and/or AGT genes. 

 
 

A R T I C L E 2
  
    DEFINITIONS    
    

        2.1   "Diagnostic Services I" means genetic testing, including, but not limited to, BRACAnalysis®, to determine a
specific DNA sequence or sequences of the BRCA1 and/or BRCA2 gene(s) in a given individual including mutations or alterations thereof, when such determination is performed for the purpose of providing
information to physicians, healthcare practitioners and/or patients with respect to a patient's relative risks of inherited cancer or the diagnosis or monitoring of cancer; provided, however, that
Diagnostic Services I do not include: (a) Diagnostic Products (as defined in Article 2.3), and/or (b) Therapeutic Products (as defined in Article 2.13); and/or
(c) activities in which the DNA sequences of one or more individuals are ascertained for purposes other than evaluating a patient's relative risks of inherited breast and ovarian cancer or
diagnosing or monitoring breast and ovarian cancer (for example, developing Diagnostic Products and/or Therapeutic Products). 

        2.2   "Diagnostic Services II" means current and future genetic testing developed and commercialized by Myriad, including, but
not limited to, COLARISSM, COLARIS APSM, MELARISSM, CardiaRisk®, and other genetic testing
to determine a specific DNA sequence or sequences of the MLH1, MSH2, APC, P16 and/or AGT gene(s) in a given individual including mutations or alterations thereof, when such determination is performed
for the purpose of providing information to physicians, healthcare practitioners and/or patients with respect to a patient's relative health risks, or the diagnosis or monitoring of such health risks;
provided, however, that Diagnostic Services II do not include: (a) Diagnostic Products (as defined in Article 2.3), and/or (b) Therapeutic Products (as defined in 

 

Article 2.13);
and/or (c) activities in which the DNA sequences of one or more individuals are ascertained for purposes other than evaluating a patient's relative health risks, or
diagnosing or monitoring such health risks (for example, developing Diagnostic Products and/or Therapeutic Products). 

        2.3   "Diagnostic Products" means any reagent, article, equipment and/or apparatus that (i) is used, either alone or in
combination with other reagents, articles and/or equipment, to determine the specific DNA sequence or sequences of genes in a given individual, including mutations thereof and relative risks of
cancer, and (ii) is sold to a customer who actually performs a test to determine a DNA sequence or sequences of the genes in a given individual, including mutations thereof and relative risks
of cancer or high blood pressure, without the provision from the maker or distributor of such products of any testing or interpretive services covering such DNA sequences. 

        2.4   "Full Sequence Testing" means any analytical method of determining the sequence of a gene. 

        2.5   "Improvement" means any discovery or invention made by GTG or GTG Subsidiaries relating to an improvement in, or a new
use or application of, or a new method of determining a specific DNA sequence or sequences of the BRCA1, BRCA2, MLH1, MSH2, APC, P16 and/or AGT gene(s), including but not limited to the discovery of
any novel mutations of the BRCA1, BRCA2, MLH1, MSH2, APC, P16 and/or AGT gene(s). 

        2.6   "Licensed Patents" means patents owned, licenseable, or sub-licensable by Myriad, and claiming (i) a
BRCA1, BRCA2, MLH1, MSH2, APC, P16, AGT or other gene sequence which is the coding sequence or the genomic sequence set forth in the sequence listing of a patent as specifically limited by that base
discovered at each of a specific set of polymorphic sites along the coding or genomic sequence, (ii) mutations, polymorphisms, alterations and variants in, such BRCA1, BRCA2, MLH1, MSH2, APC,
P16, AGT, or other sequences; or (iii) processes and methods for using (i) and (ii), and all divisions, continuations, continuations-in-part, reexaminations, and
reissues of such patents. 

        2.7   "Myriad Testing Services" means all genetic testing services performed by Myriad. 

        2.8   "Net Revenues" means gross revenues recognized in accordance with generally accepted accounting principles for Diagnostic
Services I and/or Diagnostic Service II, less governmental and healthcare rebates, and hospital, insurance company and HMO performance incentive program rebates. 

        2.9   "Southeast Asia" means the region of Asia bounded by the Indian subcontinent on the west, China on the north, and the
Pacific Ocean on the east, including Indochina, the Malay Peninsula, and the Malay Archipelago, including the countries of Singapore, Malaysia, Indonesia, Brunei, Burma (Myanmar), Cambodia, Laos, The
Philippines, Thailand, and Vietnam. 

        2.10 "Specific Mutation Testing" means site-specific detection of a predetermined, known mutation of a gene. 

        2.11 "Subsidiaries" means any corporation, company or other legal entity, in which more than fifty percent (50%) of the
shares entitled to vote for the election of directors or persons performing similar functions are, now or hereafter, owned or controlled, directly or indirectly by a Party hereto, or jointly by the
Parties hereto; provided, however, that any corporation, company or other legal entity shall be a Subsidiary only for as long as such ownership or control exists. 

        2.12 "Territory" means Australia and New Zealand. 

        2.13 "Therapeutic Products" means compositions of matter, including but not limited to DNA sequences, proteins or
polypeptides produced from such DNA sequences or vectors harboring such DNA sequences, intended for either preventing or treating various forms of cancer or high blood pressure. 

        2.14 "Third Party" means any person or entity other than Myriad, GTG, and GTG's Subsidiaries. 

2

 

 
 

A R T I C L E 3
  
    LICENSE GRANT    
    

        3.1   Myriad
grants GTG and GTG's Subsidiaries the exclusive (except as provided in Article 3.8) right and license under Licensed Patents issued in the Territory to
market, sell, offer to sell, and import Diagnostic Services II performed by Myriad, including Full Sequence Testing and Specific Mutation Testing. 

        3.2   Myriad
grants GTG and GTG's Subsidiaries an exclusive (except as provided in Article 3.8), fee-bearing, non-transferable (except as
provided in Article 7.1) right and license under Licensed Patents issued in the Territory to market, sell, offer to sell, perform, and import Diagnostic Services I, including Full Sequence
Testing, Specific Mutation Testing, and Myriad Testing Services, in the Territory. 

        3.3   Myriad
grants GTG and GTG's Subsidiaries an exclusive (except as provided in Article 3.8), fee-bearing, non-transferable (except as
provided in Article 7.1) right and license under Licensed Patents issued in the Territory to market, sell, offer to sell, perform, and import Diagnostic Services II, limited to Specific
Mutation Testing, in the Territory. 

        3.4   GTG
shall pay Myriad an annual fee of One Hundred Thousand United States Dollars (US$100,000) on each anniversary date of the Effective Date as consideration for the
marketing rights granted in Article 3.1 and the rights and licenses granted in Articles 3.2 and 3.3. 

        3.5   The
rights and licenses granted under Articles 3.1, 3.2, and 3.3 of this Agreement exclude the right to grant sublicenses. 

        3.6   During
the term of this Agreement GTG shall have the right to prosecute, at GTG's own expense, any infringement of Licensed Patents issued in the Territory and to
collect damages for such infringement, provided that: 

        3.6.1 GTG
provides Myriad with written notice identifying (a) the alleged infringer, and (b) the alleged infringer's accused products, and (c) the
specific claims of the Licensed Patents that GTG intends to assert against the alleged infringer's accused products, and (d) reasonable evidence of infringement; and 

        3.6.2 Within
ninety (90) days of the notice specified in Article 3.6.1 of this Agreement, Myriad elects not to prosecute the alleged infringer identified by
GTG and notifies GTG in writing that Myriad has elected not to prosecute the alleged infringer; and 

        3.6.3 GTG
shall be responsible for the total cost of any infringement action brought by GTG; and 

        3.6.4 GTG
shall pay Myriad fifty percent (50%) of any cash amount actually received by GTG as an award in any action or in settlement of any action brought by GTG for
infringement of the Licensed Patents; provided, however, that the total value of any cash paid to Myriad by GTG shall be reduced by the amount of the total out-of-pocket fees
and costs incurred by GTG in the prosecution and/or defense of the Licensed Patents in any such action; and 

        3.6.5 No
settlement, consent judgment or other voluntary final disposition of any action for infringement of the Licensed Patents or any declaratory judgment action alleging
invalidity or non-infringement of the Licensed Patents may be entered into without the consent of Myriad, which consent shall not be unreasonably withheld. 

        3.7   No
right or license is granted by Myriad to GTG under this Agreement, by implication or by estoppel, or otherwise to any patents, inventions, patent application,
know-how, technology, trademark, 

3

 

copyright,
trade secret, or other property right, other than the rights and licenses expressly granted in Articles 3.1, 3.2, 3.3, 3.6, and 5 of this Agreement. 

        3.8   GTG
shall use commercially reasonable and timely efforts to commercialize Diagnostic Services I and Diagnostic Services II in the Territory, and in the event that GTG or
a GTG Subsidiary does not commercialize Diagnostic Services I and Diagnostic Services II in the Territory within two (2) years of the Effective Date, the rights and licenses granted in
Articles 3.1, 3.2, and 3.3 of this Agreement shall convert to non-exclusive rights and licenses and the right to sue infringers provided under Article 3.6 of this Agreement
shall be revoked. 

        3.9   Myriad
shall use reasonable efforts to maintain the Licensed Patents in the Territory, including, but not limited to, paying all maintenance and/or annuity fees. 

        3.10 Improvements. GTG and/or GTG's Subsidiaries shall promptly provide Myriad with a complete disclosure of all
Improvements. 

        3.10.1   At
the request of Myriad, GTG and/or GTG's Subsidiaries shall grant Myriad an exclusive, fully-paid, royalty-free, perpetual
right and license under all applicable patent and other proprietary rights relating to such Improvement(s), to make, have made, use, sell, offer for sale, market, perform, and import Diagnostic
Services I and/or Diagnostic Services II, including Full Sequence Testing and Specific Mutation Testing, in all jurisdictions other than those jurisdictions in which GTG and GTG's Subsidiaries have
exclusive rights or an option to obtain exclusive rights. 

        3.10.2   If
GTG and/or GTG's Subsidiary elects not to obtain patent coverage for an Improvement, GTG and/or GTG's Subsidiary shall provide Myriad with the
opportunity to prepare and file appropriate patent applications covering the Improvement. 

        3.10.3   GTG
and/or GTG's Subsidiaries shall require all employees to assign all inventions made by them in the course of developing, marketing, selling,
offering for sale, performing, or importing Diagnostic Services I and Diagnostic Services II to GTG and/or GTG's Subsidiaries. 

 
 

A R T I C L E 4
  
    TESTING SERVICES AND FEES    
    

        4.1   Subcontracting to Myriad. All Diagnostic Services I and/or Diagnostic Services II subcontracted by GTG or GTG's
Subsidiaries shall be subcontracted solely to Myriad, and not to any other Third Party. 

        4.1.1   All
subcontracted Diagnostic Services I and/or Diagnostic Services II shall be performed by Myriad at the prices set forth in Exhibit A; provided,
however, that: 

        4.1.1.1   Myriad
may, at Myriad's discretion, increase the prices set forth in Exhibit A, provided that such increases are consistent with increases for
Myriad's other commercial partners. 

        4.1.1.2   Myriad
shall provide GTG with prices for Diagnostic Services I and/or Diagnostic Services II as favorable as the most favorable terms provided to
current Myriad customers. 

        4.1.2   GTG
shall provide to Myriad all patient specimens required by Myriad to perform subcontracted Diagnostic Services I and/or Diagnostic Services II in the
form of whole blood or extracted DNA, and shall code such specimens using a unique alpha-numeric identifier and not the patient's name. 

        4.1.3   Myriad
shall promptly return all results of subcontracted Diagnostic Services I and/or Diagnostic Services II requested by GTG or GTG's Subsidiaries to
GTG or GTG's Subsidiary and shall be paid directly by GTG or GTG's Subsidiary in United States dollars the subcontract price 

4

 

within
thirty (30) days of the date a request to perform Full Sequence Testing and/or Specific Mutation Testing is submitted to Myriad. 

        4.2   Exclusive Commercial Relationship. In accordance with the exclusive rights and licenses granted to GTG and GTG's
Subsidiaries in this Agreement, Myriad shall not accept requests to conduct Diagnostic Services I and/or Diagnostic Services II directly from a commercial laboratory or physician originating in the
Territory or reasonably believed to have originated in the Territory, except as follows: 

        4.2.1   In
the event that Myriad receives any samples for Diagnostic Services I and/or Diagnostic Services II from a commercial laboratory or physician in the
Territory subsequent to the Effective Date, Myriad shall have the right to perform Diagnostic Services I and/or Diagnostic Services II but shall (a) immediately notify GTG of the commercial
laboratory or physician; (b) immediately notify the commercial laboratory or physician that it will not accept any additional samples in the future; and (c) refer the commercial
laboratory or physician to GTG for future testing requests. 

        4.2.2   If
Myriad performs any Diagnostic Services I and/or Diagnostic Services II pursuant to Article 4.2.1, Myriad will credit GTG a fee in the amount
of two hundred United States Dollars (US$200.00) for such Diagnostic Services I and/or Diagnostic Services II. 

        4.3   Regulatory Approvals. GTG shall obtain all data necessary for and shall obtain all applicable regulatory approvals
required to be filed with any applicable government regulatory authority in the Territory to obtain or maintain permission to perform Diagnostic Services I and/or Diagnostic Services II. All research
and clinical studies required for regulatory approval in the Territory shall be conducted at the sole cost of GTG. Myriad shall cooperate with and provide reasonable assistance to GTG in obtaining
such regulatory approvals. 

        4.4   Marketing. GTG shall be responsible for preparing educational materials relating to Diagnostic Services I and/or
Diagnostic Services II and appropriate to the Territory, and distributing such educational materials in the Territory. GTG shall assign all copyright rights to all such marketing and educational
materials to Myriad. All marketing and educational materials shall bear the name of Myriad in an equally prominent size and position as the name of GTG and/or GTG's Subsidiaries. 

        4.5   Insurance. Myriad shall not be responsible for negotiating or obtaining reimbursement from insurance carriers (including
governmental insured health care systems). Myriad shall, if requested by GTG, provide reasonable assistance to GTG, at GTG's expense, in negotiating such reimbursement for GTG's benefit. 

        4.6   Genetic Counseling. Myriad shall not be responsible for providing genetic counseling services with respect to Diagnostic
Services I and/or Diagnostic Services II provided by GTG or GTG's Subsidiaries in the Territory. All such genetic counseling shall be provided pursuant to applicable laws and regulations within the
Territory. 

        4.7   Reporting Results to Research Databases. With respect to Diagnostic Services I and/or Diagnostic Services II performed by
Myriad for GTG or GTG's Subsidiaries, Myriad shall have the right to report applicable mutations detected to applicable research database service providers. Myriad will notify GTG of all such
mutations reported. 

        4.8   Quality Laboratory Practices. GTG and GTG's Subsidiaries shall maintain quality laboratory practices in providing
Diagnostic Services I and/or Diagnostic Services II in accordance with reasonable guidelines provided by Myriad. Myriad shall have the right at any time, upon reasonable notice to GTG and/or GTG's
Subsidiaries and at times and places reasonably acceptable to GTG and/or GTG's Subsidiaries, to audit the laboratory practices of GTG and/or GTG's Subsidiaries once per Calendar Quarter. In the event
that Myriad determines that such laboratory practices are deficient, Myriad shall 

5

 

notify
GTG and/or GTG's Subsidiaries of steps required to correct such deficiencies and GTG and/or GTG's Subsidiaries shall have the right to make such corrections within sixty (60) days
following notice from Myriad. Myriad shall have the right to conduct one or more audits (in addition to the audit permitted once per Calendar Quarter) in order to confirm that steps have been taken to
correct the deficiencies. Failure of GTG and/or GTG's Subsidiaries to correct such deficiencies within such sixty day period shall constitute material breach of this Agreement. 

        4.9   Insurance. GTG shall procure and maintain, at GTG's sole expense, liability insurance covering the activities of GTG
(1) in providing Diagnostic Services I and/or Diagnostic Services II in the amounts equivalent to One Million United States Dollars (US$1,000,000) per occurrence and Three Million United States
Dollars (US$3,000,000) aggregate and (2) comprehensive general and/or umbrella liability insurance in the amount of One Million United States Dollars (US$1,000,000) per occurrence and
aggregate. 

 
 

A R T I C L E 5
  
    OPTION GRANTS    
    

        5.1   Myriad
grants GTG an option, exercisable prior to the third anniversary of the Effective Date, for GTG to expand the license granted in Article 3.3 to include
Full Sequence Testing performed by GTG and/or GTG's Subsidiaries. In the event that GTG exercises this option, GTG shall: 

        5.1.1   Pay
Myriad an up-front license fee of three hundred thousand United States Dollars (U.S. $300,000); and 

        5.1.2   Pay
to Myriad royalties of five percent (5%) of GTG's Net Revenues for Diagnostic Services II Full Sequence Testing; and 

        5.1.3   Keep
full and accurate records of Diagnostic Services II Full Sequence Testing in the Territory, and furnish Myriad, within forty-five
(45) days after the last day of June and December of each calendar year, a report showing the basis upon which royalty payments are paid, and to accompany such report with the payment of the
royalty accrued. To enable Myriad to verify the accuracy of such reports, GTG agree to permit an independent certified public accountant, no more often than once per calendar year, to inspect GTG's
pertinent records at GTG's place(s) of business during reasonable business hours and at Myriad's expense; provided, however, that the report of such accountant to Myriad shall be confined to
statements regarding the accuracy of royalty payments made by GTG. In the event that the report of such accountant indicates an underpayment of royalties, GTG shall immediately pay Myriad the amount
of the underpayment and interest on the underpayment at the rate of the U.S. Prime Rate plus three percent (3%). 

        5.2   Myriad
grants GTG an option, exercisable prior to the third anniversary of the Effective Date, for GTG to obtain an exclusive, royalty-bearing,
non-transferable (except as provided in Article 7.1) right and license to market, sell, offer to sell, perform, and import Diagnostic Services I, limited to Specific Mutation
Testing, in Singapore, Malaysia and Indonesia on terms and conditions to be negotiated in good faith, which shall include the following terms and conditions: 

        5.2.1   In
the event that GTG exercises this option, GTG shall pay Myriad an up-front fee of Three Hundred Thousand United States Dollars (U.S.
$300,000); 

        5.2.2   GTG
will pay to Myriad royalties of three percent (3%) of GTG's Net Revenues in the countries of Malaysia, Singapore, and Indonesia; and 

        5.2.3   GTG
shall keep full and accurate records, provide reports, and permit inspections in the manner specified in Article 4.1.3 with respect to
revenues for Diagnostic Services I in Malaysia, Singapore, and Indonesia. 

6

 

        5.3   Myriad
grants GTG an option, exercisable prior to the fifth anniversary of the Effective Date, for GTG to obtain an exclusive, fully-paid,
non-transferable (except as provided in Article 6.1) right and license to market, sell, offer to sell, import, and perform Diagnostic Services I only for Specific Mutation Testing,
in Southeast Asia (excluding Singapore, Malaysia and Indonesia) on terms and conditions to be negotiated in good faith. 

 
 

A R T I C L E 6
  
    TERM AND TERMINATION    
    

        6.1   The
term of this Agreement and the rights and licenses granted by this Agreement shall extend until the anniversary of the Effective Date in the year 2012. 

        6.2   Either
party shall have the right to terminate this Agreement upon any material breach of any term or condition of this Agreement by the other party, which has not been
corrected within thirty (30) days after receipt of a notice in writing. 

        6.3   In
the event that GTG fails to make any payment required under this Agreement, Myriad shall have the right to terminate this Agreement and the licenses and rights
granted under this Agreement by providing written notice of termination; provided, however, that such notice of termination shall not be effective if the required payment is made within thirty
(30) days after receipt of the written notice. 

        6.4   In
the event of a termination of this Agreement under Article 6.3, Myriad shall be relieved of all obligations to make payments to GTG under the License Agreement
between GTG and Myriad having an Effective Date of                        . 

        6.5   In
the event of termination of this Agreement all rights granted to GTG hereunder shall revert to Myriad. 

        6.6   This
Agreement, the licenses granted under this Agreement, and the payment obligations set forth in this Agreement shall survive the invalidity and/or the
unenforceability of the Licensed Patents. 

 
 

A R T I C L E 7
  
    TRANSFERABILITY    
    

        7.1   GTG
shall not transfer this Agreement or the license and rights granted to GTG under this Agreement to any third party, by agreement, assignment, merger, asset sale,
consolidation, operation of law, or otherwise, without the prior written consent of Myriad; provided, however, that GTG may transfer this Agreement to a successor in ownership of all or substantially
all of the assets of GTG, if the successor expressly assumes in writing GTG's obligations under this Agreement. 

 
 

A R T I C L E 8
  
    REPRESENTATIONS AND WARRANTIES    
    

        8.1   Myriad
represents and warrants that Myriad has the full right, power, and authority to enter into and perform its obligations under this Agreement and grant to GTG the
license and other rights as set forth herein, and there are no outstanding agreements, grants, licenses, encumbrances, liens, or agreements, either written or implied, inconsistent therewith or
pursuant to which this Agreement or the parties' performance hereunder would violate, breach, or cause a default. Myriad further represents and warrants that Myriad is not aware of any patents owned,
licenseable, or sub-licensable by Myriad (other than Licensed Patents) that may be infringed by marketing, using, selling, offering to sell, importing, or performing Diagnostic Services I
and/or Diagnostic Services II. 

7

 

        8.2   The
execution, delivery, and performance of this Agreement have been duly authorized by all necessary corporate actions on the part of Myriad. 

        8.3   GTG
represents and warrants that GTG has the full right, power, and authority to enter into and perform GTG obligations under this Agreement, and there are no
outstanding agreements, grants, licenses, encumbrances, liens, or agreements, either written or implied, inconsistent therewith or pursuant to which this Agreement or the parties' performance
hereunder would violate, breach, or cause a default. 

        8.4   The
execution, delivery, and performance of this Agreement have been duly authorized by all necessary corporate actions on the part of GTG. 

        8.5   DISCLAIMER
OF WARRANTIES. Except as expressly set forth herein, each party expressly disclaims, to the extent allowed by applicable law, any and all warranties of any
kind, express or implied, including without limitation the warranties of design, merchantability, fitness for a particular purpose (even if informed of such purpose), noninfringement of the
intellectual property rights of third parties, or arising from a course of dealing, usage or trade practices, in all cases with respect thereto. 

        8.6   LIMITATION
OF LIABILITY. Except for breach of payment terms under Articles 3 and/or 4 or for liability for breach of any confidentiality provisions in this agreement,
neither party shall be entitled to recover from the other party any special, incidental, consequential or punitive damages in connection with this Agreement or any license granted hereunder. 

        8.7   Nothing
in this Agreement shall be construed as: 

        8.7.1   a
representation or warranty by Myriad of the validity, enforceability or scope of any Licensed Patents; or 

        8.7.2   a
requirement that Myriad shall file any patent application or secure any patent; or 

        8.7.3   a
representation or warranty that any product made, used, sold, or otherwise disposed of by GTG is free from infringement of patents of third parties; or 

        8.7.4   an
obligation of Myriad to bring or prosecute actions or suits against third parties for infringement of any patent; or 

        8.7.5   inferring
a right of GTG to use in advertising, publicity, or otherwise any trademark or trade name of Myriad. 

 
 

A R T I C L E 9
  
    ARBITRATION    
    

        9.1   Any
controversy or claim arising from a breach of this Agreement shall be settled by arbitration in accordance with the rules of the American Arbitration Association,
and judgment upon the award rendered by the arbitrators may be entered in any court in California having jurisdiction thereof. This arbitration agreement shall not apply to any controversy or claim
involving an issue of the infringement, validity, or enforceability of any patent. The arbitration shall be governed by the United States Arbitration Act, 9 U.S.C.
§§.1-16, to the exclusion of any provisions of state law inconsistent therewith or which would produce a different result. 

        9.1.1   A
single arbitrator shall be selected by agreement between the parties. If the parties fail to agree on an arbitrator, a single arbitrator shall be
selected in accordance with the procedures set forth in the Arbitration Rules. The arbitrator shall render a final award in accordance with the substantive law of the State of California, excluding
the conflicts provisions of such law. 

8

 

        9.1.2   The
arbitrator shall be fully compensated in accordance with his or her normal hourly or per diem rates for all time spent in connection with the
arbitration proceeding. Pending a final award, the arbitrator's compensation and expenses shall be advanced equally by the parties. 

        9.1.3   The
parties may request a court for interim or provisional relief, and any such request shall not be deemed incompatible with the agreement to arbitrate
or as a waiver of that agreement. 

        9.1.4   In
no event will the arbitrator have the power to include any element of punitive damages or incidental or consequential damages in the arbitration
award. 

 
 

A R T I C L E 10
  
    GENERAL PROVISIONS    

        10.1 The
Parties shall keep the terms of this Agreement confidential except where disclosure is required by law, legal process or tax purposes or where the disclosure is
made pursuant to an undertaking or understanding of confidentiality. Each Party agrees that it will not make a public announcement of this Agreement without the approval of the other party. 

        10.2 Any
notices shall be deemed to be delivered when the notice is personally delivered, delivered by a commercial delivery service, received via certified or registered
mail, return receipt requested, or received via facsimile. Notices shall be addressed as follows: 

	Notices to Myriad	 	Notices to GTG	 	 
	

Myriad Genetics, Inc.

Attention: General Counsel

320 Wakara Way

Salt Lake City, Utah 84108

Facsimile: 801.584.3640	
 	

Dr. Mervyn Jacobson

Executive Chairman

Genetic Technologies Limited

60-66 Hanover Street

Fitzroy, Victoria 3065

Australia

Facsimile:	
 	

 
	

With a copy to

George A. Riley, Esq

O'Melveny & Myers LLP

275 Battery Street

San Francisco, California 94111

Facsimile: 415.984.8701	
 	

With a copy to

Michael A. DeSanctis, Esq.

Faegre & Benson LLP

Seventeenth Street, Suite 2500

Denver, Colorado 80202

Facsimile: 303.607.3600

	
 	

 

        10.3 Any
waiver by either Party of the breach of any term or condition of this Agreement will not be considered as a waiver of any subsequent breach of the same or any other
term or condition hereof. 

        10.4 Neither
Party will be in breach hereof by reason of its delay in the performance of or failure to perform any of its obligations hereunder, if that delay or failure is
caused by strikes, acts of God or the public enemy, riots, or any other fault beyond its control or without its fault or negligence. 

        10.5 This
Agreement constitutes the entire understanding of the Parties with respect to the subject matter and supersedes all prior and contemporaneous oral or written
negotiations, agreements and understandings. 

        10.6 This
Agreement may not be modified or amended except in writing signed by authorized persons on behalf of the Parties. 

        10.7 The
validity, construction, interpretation and performance of this Agreement, and any disputes or legal actions arising thereunder or therefrom, shall be governed by
the laws and regulations of the 

9

 

United
States of America and the State of California without regard to conflict of law doctrines. Each Party submits to jurisdiction in San Francisco, California and the United States District Court
for the Northern District of California with respect to any claims arising out of this Agreement. 

        10.8 The
Parties acknowledge that each Party has been represented by counsel in connection with this Agreement. Accordingly, any rule of law that would require
interpretation of any claimed ambiguities in this Agreement against the Party that drafted it has no application and is expressly waived. 

        10.9 This
Agreement can be executed in counterparts, including those transmitted by facsimile, and each counterpart will be considered an original. 

        10.10 Unless
the context clearly requires a different interpretation, words denoting the singular will include the plural and vice versa; words denoting any gender will
include all genders; words denoting persons will include corporations, partnerships, joint ventures, proprietorships and other business entities. 

[REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] 

10

 

IN
WITNESS THEREOF, each of the Parties has caused this Agreement to be executed by its duly authorized representative. 

MYRIAD
GENETICS, INC. 

Dated:
October    , 2002 

	

 	
 	

By:	

    

	 	 	Name:	Peter Meldrum

	 	 	Title:	President and Chief Executive Officer
	 	 	 	

GENETYPE
AG 

Dated:
October    , 2002 

	

 	
 	

By:	

    

	 	 	Name:	Mervyn Jacobson

	 	 	Title	 
	 	 	 	

GENETIC
TECHNOLOGIES LIMITED 

Dated:
October    , 2002 

	

 	
 	

By:	

    

	 	 	Name:	Mervyn Jacobson

	 	 	Title	 
	 	 	 	

11

 
 
 

Exhibit A    
    

	Test
	 	Fee

	

 	
 	

 

12

QuickLinks

Exhibit 4.6

Myriad/Genetic Technologies Marketing and Patent License Agreement

A R T I C L E 1 BACKGROUND

A R T I C L E 2 DEFINITIONS

A R T I C L E 3 LICENSE GRANT

A R T I C L E 4 TESTING SERVICES AND FEES

A R T I C L E 5 OPTION GRANTS

A R T I C L E 6 TERM AND TERMINATION

A R T I C L E 7 TRANSFERABILITY

A R T I C L E 8 REPRESENTATIONS AND WARRANTIES

A R T I C L E 9 ARBITRATION

A R T I C L E 10 GENERAL PROVISIONS

Exhibit A

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00089-of-00352.parquet"}]]